Importantly, an increasing menu of highly CNS-active targeted therapies including for EGFR-variant and ALK-rearranged malignant neoplasms allows a growing proportion of patients to avoid metastasectomy and/or brain radiation. The gene discussed is EGFR; the disease is cancer.